血小板生成素受体激动剂在老年原发免疫性血小板减少症中的真实世界应用
该研究纳入384例年龄≥60岁的原发免疫性血小板减少症(ITP)患者,评估血小板生成素受体激动剂(TRA)的疗效与安全性。3个月时艾曲泊帕组82.5%、罗米司亭组74.3%获得应答,66.7%维持应答;22.2%患者换用另一种TRA,耐药者换药后83.3%获得应答。TRA在老年ITP患者中有效,无致死性出血,部分患者可获得停药后持续缓解,但有血栓史者需谨慎。
要点
- 老年ITP患者TRA 3个月应答率较高,多数可维持应答
- 耐药患者换用另一种TRA后多数仍可获得应答
- 有血栓史者TRA治疗期间血栓风险升高,需权衡风险获益
核心结论
- TRA在老年ITP患者中有效,无致死性出血,相当比例患者可获得停药后持续缓解。
- 有血栓史的患者使用TRA需谨慎,应仔细权衡风险与获益。
研究设计与样本
- 回顾性真实世界研究,纳入384例年龄≥60岁的原发免疫性血小板减少症患者。
- 评估TRA应答与换药、血栓/出血风险及停药后持续缓解(SROT)。
主要发现
- 治疗3个月时,艾曲泊帕组82.5%、罗米司亭组74.3%的患者获得应答,66.7%维持应答(中位随访2.7年)。
- 血栓与TRA启动时血栓史相关(亚分布风险比2.04,P = .05),重大出血与血小板计数<20 × 109/L相关(亚分布风险比1.69,P = .04)。
- 血栓存活者中15.6%复发,除1例外均发生在持续TRA治疗期间(发生率7.7/100患者年),且均缺乏充分的抗血栓二级预防。
关键数值与推荐
- 3个月应答率:艾曲泊帕82.5%,罗米司亭74.3%;维持应答66.7%(中位随访2.7年)。
- 换药:22.2%患者换用另一种TRA,耐药者换药后应答率83.3%。
- 血栓史与血栓事件的亚分布风险比2.04(P = .05);血小板计数<20 × 109/L与出血事件的亚分布风险比1.69(P = .04)。
- 血栓复发率15.6%,发生率7.7/100患者年;SROT率13.8%,与完全缓解时停药相关(P < .001)。
临床怎么用
- 老年ITP患者可考虑使用TRA,疗效较好且无致死性出血。
- 有血栓史者启动TRA前应评估血栓风险并谨慎决策。
- 血小板计数<20 × 109/L者需关注出血风险。
- 应答患者停药后部分可获得持续缓解,完全缓解时停药与SROT相关。
局限性
- 为真实世界研究,原文未报告具体研究设计类型与对照设置。
- 原文未报告TRA剂量、治疗持续时间及随访完整率等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patients with primary immune thrombocytopenia (ITP) are unknown. We investigated TRA response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROTs) in 384 patients with ITP aged ≥60 years. After 3 months, 82.5% and 74.3% of eltrombopag- and romiplostim-treated patients, respectively, achieved a response; 66.7% maintained the response (median follow-up, 2.7 years). Eighty-five (22.2%) patients switched to the alternative TRA; although no cross-toxicity was observed, 83.3% of resistant patients had a response after the switch. Thirty-four major thromboses (3 fatal) and 14 major hemorrhages (none fatal) occurred in 18 and 10 patients, respectively, while on TRAs and were associated with thrombosis history (subdistribution hazard ratio, 2.04, P = .05) and platelet count <20 × 109/L (subdistribution hazard ratio, 1.69; P = .04), respectively, at TRA start. A recurrent event occurred in 15.6% of patients surviving thrombosis, in all cases but 1 during persisting TRA treatment (incidence rate, 7.7 per 100 patient-years). All recurrences occurred in the absence of adequate antithrombotic secondary prophylaxis. Sixty-two (16.5%) responding patients discontinued TRAs; 53 (13.8%) patients maintained SROTs, which were associated with TRA discontinuation in complete response (P < .001). Very old age (≥75 years; 41.1%) was associated with the more frequent start of TRAs in the persistent/acute phase but not with response or thrombotic/hemorrhagic risk. TRAs are effective in older patients with ITP, with no fatal hemorrhages and with SROTs in a significant portion of patients. Caution is warranted in patients with a history of thrombosis, and a careful risk/benefit balance should be considered.
引用
- Palandri F, Rossi E, Bartoletti D, et al. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood. 2021. PMID: 33889952. doi:10.1182/blood.2021010735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。